Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel

HOUSTON, TX, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that its Gen-2 Console (“SYNC”), 15 milliamp (mA) neurostimulation device has been granted regulatory approval for sale in Israel by the Israeli Ministry of Health. Mark White, CEO of Nexalin Technology, stated, “We are extremely proud to have received regulatory clearance in Israel, which is recognized ...